Phase II SWOG-S0601 Trial of R-CHOP and Bortezomib Induction Therapy Followed by Bortezomib Maintenance in Previously Untreated MCL


Phase II SWOG-S0601 Trial of R-CHOP and Bortezomib Induction Therapy Followed by Bortezomib Maintenance in Previously Untreated MCL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Till BG et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. Proc ASH 2014;Abstract 149.

Dr Ansell is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota.